US Stock MarketDetailed Quotes
HOTH Hoth Therapeutics
- 1.2100
- -0.0190-1.55%
Close May 3 16:00 ET
5.92MMarket Cap-526P/E (TTM)
1.2700High1.1600Low73.40KVolume1.2202Open1.2290Pre Close89.89KTurnover1.70%Turnover RatioLossP/E (Static)4.89MShares4.300052wk High0.67P/B5.24MFloat Cap0.990052wk Low--Dividend TTM4.33MShs Float347.0000Historical High--Div YieldTTM8.95%Amplitude0.9900Historical Low1.2240Avg Price1Lot Size
About Hoth Therapeutics Company
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
Company Profile
SymbolHOTH
Company NameHoth Therapeutics
Listing DateFeb 15, 2019
Issue Price5.60
Founded2017
CEOMr. Robb Knie
MarketNASDAQ
Employees6
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address590 Madison Avenue,21st floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10020
Phone1-646-756-2997
Company Executives
- Name
- Position
- Salary
- Robb Knie
- Director, President and Chief Executive Officer
- 1.06M
- David S. Briones
- Chief Financial Officer and Principal Accounting Officer
- --
- Graig Springer
- Independent Director
- 65.34K
- David B. Sarnoff
- Independent Director
- 59.34K
- Dr. Jeff Pavell, M.D.
- Independent Director
- 3.40K
- Wayne D. Linsley
- Independent Director
- 59.34K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg